UMIN-CTR Clinical Trial

Recruitment status Completed
Unique ID issued by UMIN UMIN000019574
Receipt No. R000021795
Official scientific title of the study Effect of Denosumab and Alendronate on glucocorticoid-induced osteoporosis in patients with glomerulonephritis:a randomized controlled trial
Date of disclosure of the study information 2015/10/30
Last modified on 2017/04/28 (Ver. 5)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Official scientific title of the study Effect of Denosumab and Alendronate on glucocorticoid-induced osteoporosis in patients with glomerulonephritis:a randomized controlled trial
Title of the study (Brief title) Effect of Denosumab and Alendronate on glucocorticoid-induced osteoporosis in patients with glomerulonephritis:a randomized controlled trial
Region
Japan

Condition
Condition Glucocorticoid-Induced Osteoporosis
Classification by specialty
Medicine in general Endocrinology and Metabolism Nephrology
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 The aim of this study is to evaluate the effect of denosumab and alendronate on glucocorticoidiunduced osteoporosis in patients with glomerulonephritis.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1 Exploratory
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Percent change of bone mineral density (BMD) in lumber spine, femoral neck and distal radius at 6, 12 month after intervention
Key secondary outcomes Percent change of bone metabolism markers, rate of continuation, side effect at 6, 12 month after intervention

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Open -no one is blinded
Control Active
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 2
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 denosumab (60 mg) subcutaneously every
6 months
Interventions/Control_2 Alendronate (35 mg) by oral administration once a week
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1) patients who meet the glucocorticoid- induced osteoporosis criteria
2) Patient whose age is more than 20 years old
Key exclusion criteria 1) Patients who are considered to be contraindicated for denosumab.
2) Patients who are considered to be contraindicated for alendronate.
3) Cancer patients.
4) Patients who have pretreated with bisphosphonate in recent 6 months.
5) Patients who have pretreated with denosumab in recent 6 months.
6) Patients whose eGFR is less than 35ml/min/1.73m2.
7) Patients whose i-PTH is more than 300ml/min.
8) Patients whose corrected Ca is less than 8.4 mg/dL.
9) Patients who are thought to be inappropriate for this study by physician.
Target sample size 30

Research contact person
Name of lead principal investigator Masayuki Iyoda
Organization Showa University School of Medicine
Division name Division of Nephrology, Department of Medicine
Address 1-5-8 Hatanodai, Shinagawa-ku, Tokyo
TEL 03-3784-8533
Email iyoda@med.showa-u.ac.jp

Public contact
Name of contact person Ken Iseri
Organization Showa University School of Medicine
Division name Division of Nephrology, Department of Medicine
Address 1-5-8 Hatanodai, Shinagawa-ku, Tokyo
TEL 03-3784-8533
Homepage URL
Email iseriken@med.showa-u.ac.jp

Sponsor
Institute Showa University School of Medicine
Institute
Department

Funding Source
Organization none
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2015 Year 10 Month 30 Day

Progress
Recruitment status Completed
Date of protocol fixation
2015 Year 08 Month 28 Day
Anticipated trial start date
2015 Year 10 Month 30 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Related information
URL releasing protocol
Publication of results Unpublished
URL releasing results
Results
Other related information

Management information
Registered date
2015 Year 10 Month 30 Day
Last modified on
2017 Year 04 Month 28 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021795